Korean J Med.
2006 Oct;71(4):449-455.
A case of interstitial lung diseasec caused by Rituximab in non-Hodgkin lymphoma
- Affiliations
-
- 1Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. csuh@amc.seoul.kr
- 2Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Abstract
- Rituximab targets CD20+ B cells and has been used increasingly for the treatment of B-cell Non-Hodgkin Lymphoma, alone or in combination with cytotoxic agents. Rituximab can kill CD20+cells by multiple mechanisms. Rituximab therapy has often been associated with an infusion-related symptom complex consisting of fever, chills, and rigors that is usually self-limited. These complications are transient without long-term effects. Several delayed pulmonary events involving interstitial reactions and bronchiolitis obliterans with organizing pneumonia have recently been described in conjunction with the use of Rituximab. In the lymphoma patient presented here there was no respiratory symptoms; however, respiratory difficulty developed after the third round of Rituximab plus CHOP chemotherapy. High resolution computed tomography (HRCT) and positive emission tomography (PET) were performed and revealed diffuse ground glass opacities. We report a patient with Non-Hodgkin Lymphoma in whom interstitial lung disease developed after Rituximab therapy.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy
- A Case of Organizing Pneumonia Associated with Rituximab
- A Case of Prolonged Hypogammaglobulinemia after Rituximab-Containing Chemotherapy in a Patient with Lymphoma
- Rituximab-induced Interstitial Pneumonitis in a Young Patient: A Case Report and Review of the Literature
- A Case of Mantle Cell Lymphoma Treated with Autologous Stem Cell Transplantation and Rituximab
